- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07802600
Clinical, Dermoscopic, and Mycological Characteristics of Tinea Capitis in Children
Clinical, Dermoscopic, and Mycological Characteristics of Tinea Capitis in Children: A Cross-sectional Study
Study Overview
Status
Conditions
Detailed Description
Clinical types of tinea capitis include : scaly type (characterized by fine scaling and circular alopecia), black dot (characterized by non-inflammatory patches with broken-off, swollen hair stubs), tinea agminate (patchy alopecia with scattered pustules or low-grade folliculitis), kerion (painful, boggy, inflammatory masses with alopecia, often confused with bacterial abscess) and favus (scutula, mousy odor) . Tinea incognito (steroid modified tinea) refers to dermatophytosis that has lost their usual clinical appearance due to the use of steroids.
The main clinical feature of dermatophyte scalp infections is the appearance of scaling of the scalp skin, which is associated with a variable degree of inflammation and itching . In some cases, the infection closely resembles seborrheic dermatitis or dandruff of the scalp. A pathognomonic feature is hair loss; hair often breaks a few millimeters or more above the skin surface. Broken or infected hairs are also slightly swollen and have a dull appearance .
Trichoscopy is a non-invasive and very useful technique for the diagnosis and follow-up of hair and scalp disorders. The presence of certain trichoscopic features allows accurate identifying of tinea capitis. In tinea capitis, specific signs can be seen like comma hair, corkscrew hair, bar code-like hair and zigzag hair . In tinea incognito trichoscopic finding include erythema, scaling, bent hair, Morse code hair, and micropustules .
Mycological examination was first performed using Potassium Hydroxide(KOH) to confirm the diagnosis of tinea capitis where the patients with positive KOH were considered to have endothrix when observing arthroconidia inside the hair shaft and ectothrix when observing arthroconidia outside the hair shaft. The fungal culture also done to accurately recognize the organism through inoculation of samples on Sabouraud medium agar (SDA) with and without chloramphenicol(nonspecific medium) . And Dermasel medium agar act as specific medium.
The increase in antifungal resistance has recently been observed worldwide and resistant strains of the dermatophytes T. rubrum and T. indotineae have spread globally, causing outbreaks of extensive, difficult to treat infections , so we need rapid and reliable diagnostic tools that provide clues regarding the causative organisms.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Noha Shafik, Assistant professor
- Phone Number: 01067261504
- Email: nohasaber@med.sohag.edu.eg
Study Contact Backup
- Name: Walaa Hemdan Abu Alhassan, Demonstrator
Study Locations
-
-
-
Sohag, Egypt
- Faculty of Medicine , Sohag university
-
Contact:
- Noha Shafik
- Phone Number: 01067261504
- Email: nohasaber@med.sohag.edu.eg
-
Contact:
- Walaa Hemdan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
The study will be conducted at the Dermatology Outpatient Clinic in Sohag University Hospitals.
Study population: The study population will be all patients with tinea capitis both male and female in childhood period, Aged 1-18 years old
Description
Inclusion Criteria:
- Both male and female in childhood period (1-18 years) with tinea capitis
Exclusion Criteria:
- Topical or systemic antifungal medications one month prior to enrollment in the study
- Presence of systemic disease, such as hepatic,renal, cardiac, autoimmune diseases, or malignancy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
patients with tinea capitis both male and female in childhood period
|
Specimen will be cultured on sabouraud's dextrose agar (SDA) at 25 -30 c for 2 to 4 weeks and another specimen will be cultured on a Dermasel agar base (Oxoid, UK), both supplemented with chloramphenicol and cycloheximide , staining the fungal colonies by Lactophenol cotton blue to help the examination of colonial morphology and microscopic examination of the macro-conidia allow the identification of the dermatophyte species and suitable treatment
Antifungal susceptibility testing will be performed to determine the specific sensitivity profiles of the fungal isolates.
Antifungal susceptibility testing will be performed using seven antifungal agents: Terbinafine, Itraconazole, Griseofulvin, Fluconazole, Ketoconazole, Vorioconole and Miconazole.
Dermatophytes colonies will be probed from Dermasel agar cultures.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of participants presenting with specific clinical patterns of tinea capitis
Time Frame: At the time of initial clinical evaluation
|
Clinical evaluation will be performed to identify and classify the presentation of tinea capitis lesions (e.g., scaly patches, black dots, kerion, favus).
|
At the time of initial clinical evaluation
|
|
Percentage of participants exhibiting specific dermoscopic features of tinea capitis
Time Frame: At the time of initial dermoscopic evaluation
|
Dermoscopic examination using a handheld dermatoscope to identify characteristic signs including comma hairs, corkscrew hairs, broken hairs, and scaling.
|
At the time of initial dermoscopic evaluation
|
|
Prevalence of isolated fungal species among pediatric tinea capitis cases
Time Frame: At the time of initial sample collection and culture identification
|
Mycological evaluation including direct microscopic KOH preparation and fungal culture on agar media to isolate and identify the causative fungal pathogens.
|
At the time of initial sample collection and culture identification
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mohammed Abu El Hamd Ali, Faculty of Medicine , Sohag university
- Study Chair: Doaa Gaber Abdelbaset, Faculty of Medicine , Sohag university
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Soh-Med-26-8-10MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.